Skip to main content

Table 4 Analysis for combinational biomarkers

From: Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Variables Combinations
Mutation+ Mutation- Mutation+ Mutation- Mutation+ Mutation- Mutation+ Mutation- P
1068+ 1068+ 1068- 1068- 1068+ 1068+ 1068- 1068- -
1173+ 1173+ 1173+ 1173+ 1173- 1173- 1173- 1173- -
Total 35(22.4) 42(26.9) 5(3.2) 8(5.1) 30(19.2) 19(12.2) 2(1.3) 15(9.6) -
ORR CR + PR 16(45.7) 7(16.7) 1(20.0) 1(12.5) 20(66.7) 5(26.3) 0 0 <0.001
DCR CR + PR + SD 28(80.0) 26(61.9) 3(60.0) 1(12.5) 29(96.7) 17(89.5) 1(50.0) 8(53.3) <0.001
PD 7(20.0) 16(38.1) 2(40.0) 7(87.5) 1(3.3) 2(10.5) 1(50.0) 7(46.7)
PFS Median (months) 6.3 3.1 4.6 1 12.8 6.6 0.4 1.4 <0.001
  1. Abbreviations: pTyr, phophorylated tyrosine; CR, complete remission; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival, 1068 pTyr1068, 1173 pTyr1173.